Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer-Reference-Cited by-同舟云学术

Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer

Published:2024-01 Issue: Volume:238 Page:115839
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Saghafi Fatemeh,Salehifar Ebrahim,Ebrahimi Pouneh,Shiran Mohammad Reza,Zaboli Ehsan,Sohrevardi Seyed Mojtaba,Jamialahmadi Tannaz,Sahebnasagh Adeleh,Sahebkar Amirhossein

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference43 articles.

1. A review of incidence and mortality of colorectal, lung, liver, thyroid, and bladder cancers in Iran and compared to other countries;Farhood;Contemp. Oncol.,2019

2. CYP2D6* 3 (A2549del),* 4 (G1846A),* 10 (C100T) and* 17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen;Saghafi;Biomed. Rep.,2018

3. Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection;Criscitiello;OncoTargets Ther.,2011

4. Hsuan J.J. Transforming Growth Factor (TGF) Alpha. 2004.

5. The mechanism of tamoxifen in breast cancer prevention;Yu,2001

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological and pharmacological functions of the metabolites of polyunsaturated fatty acids mediated by cyclooxygenases, lipoxygenases, and cytochrome P450s in cancers;Pharmacology & Therapeutics;2024-04